Athira Pharma, Inc. (NASDAQ:LONA) Given Consensus Rating of “Moderate Buy” by Brokerages

Athira Pharma, Inc. (NASDAQ:LONA) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $17.3333.

A number of analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Piper Sandler started coverage on shares of Athira Pharma in a research note on Wednesday, May 27th. They issued an “overweight” rating and a $20.00 target price for the company. Citizens Jmp lowered their price target on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a report on Monday, August 17th. Mizuho dropped their price target on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 19th. Finally, Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th.

Athira Pharma Stock Performance

LONA stock opened at $8.02 on Friday. Athira Pharma has a 1 year low of $3.52 and a 1 year high of $14.21. The firm has a market cap of $75.34 million, a P/E ratio of -1.90 and a beta of 2.05. The stock has a 50-day simple moving average of $8.00 and a 200-day simple moving average of $8.63.

Athira Pharma (NASDAQ:LONA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.20). On average, equities research analysts predict that Athira Pharma will post -2.67 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Commodore Capital LP purchased a new stake in Athira Pharma during the 4th quarter worth approximately $3,515,000. Seven Fleet Capital Management LP acquired a new position in shares of Athira Pharma in the 4th quarter valued at approximately $969,000. Spruce Street Capital LP purchased a new position in shares of Athira Pharma during the 4th quarter valued at approximately $2,980,000. Perceptive Advisors LLC boosted its stake in shares of Athira Pharma by 244.1% during the 4th quarter. Perceptive Advisors LLC now owns 1,859,322 shares of the company’s stock valued at $14,075,000 after buying an additional 1,319,026 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Athira Pharma during the fourth quarter worth approximately $2,456,000. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.